STAAR Surgical (STAA) Q2 Revenue Tops 9%

STAAR Surgical (NASDAQ:STAA), a medical device company specializing in implantable lenses for vision correction, released its earnings for Q2 FY2025 on August 6, 2025. The main news from the release is that both GAAP revenue and GAAP earnings per share came in ahead of analyst estimates, despite a sharp year-over-year drop caused by sluggish sales in China. The company reported GAAP revenue of $44.3 million, compared to an analyst expectation of $40.5 million, and a GAAP loss per share of $(0.34) versus consensus at $(0.56). Performance outside China was a bright spot, with net sales excluding China up 10% year-over-year, but management withdrew its formal financial outlook due to continuing uncertainty in China and unresolved tariff risks. The quarter reflects operational progress but also shows the ongoing challenges in returning to prior levels of profitability. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. STAAR Surgical develops and manufactures implantable lenses used to correct refractive vision problems such as myopia, offering an alternative to laser eye surgery. Its core product is the implantable Collamer lens (ICL), made from a proprietary biocompatible material. This Collamer technology is designed to be flexible and gentle on the eye, allowing for minimally invasive and reversible procedures, which distinguishes the company in the vision correction field.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool